Literature DB >> 14739017

Visceral leishmaniasis in immunocompromised patients with and without AIDS: a comparison of clinical features and prognosis.

Manuel L Fernández-Guerrero1, Pablo Robles, Pablo Rivas, Francisca Mójer, Gemma Muñíz, Miguel de Górgolas.   

Abstract

Visceral leishmaniasis is basically a disease of healthy infants and adults. However, in the last decade an increasing number of cases of kala azar in immunocompromised patients have been reported with emphasis on atypical manifestations of the disease. During a period of 11 years, 20 immunocompromised patients with AIDS (12 patient), haematological neoplasia (3 patients), corticosteroid therapy (3 patients) or renal transplantation (2 patients) were studied by one or more of the authors. We did not find differences in the presentation of leishmaniasis between patient with or without AIDS and most patients had fever, enlargement of the liver and spleen, blood cytopenias and biochemical abnormalities. Serology was more frequently positive in HIV-negative than in HIV-positive patients (100% versus 63.6%; P=0.13). Bone marrow biopsy was diagnostic in 66% and 87% of patients with and without AIDS, respectively. Failure of anti-leishmanial therapy occurred in 6 of 19 patients treated (31.5%), and 3 patients with AIDS and another 3 without AIDS died during the first episode of leishmaniasis. Of 12 survivors, relapses occurred in five (41.6%). Only patients in whom immunosuppression was ameliorated by means of antiretroviral therapy or by reduction of corticosteroid and other immunosuppressive drugs did not relapse. Treatment of kala azar in immunocompromised host is in satisfactory and new drugs or strategies are urgently needed.

Entities:  

Mesh:

Year:  2004        PMID: 14739017     DOI: 10.1016/j.actatropica.2003.09.009

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  14 in total

Review 1.  Parasitic central nervous system infections in immunocompromised hosts: malaria, microsporidiosis, leishmaniasis, and African trypanosomiasis.

Authors:  Melanie Walker; James G Kublin; Joseph R Zunt
Journal:  Clin Infect Dis       Date:  2005-11-23       Impact factor: 9.079

2.  Alternative drug treatments for visceral leishmaniasis: miltefosine.

Authors:  Mary E Wilson
Journal:  Curr Infect Dis Rep       Date:  2008-03       Impact factor: 3.725

3.  New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas.

Authors:  Kathryn M Dupnik; Eliana L Nascimento; Joao F Rodrigues-Neto; Tatjana Keesen; Maria Zélia Fernandes; Iraci Duarte; Selma M B Jeronimo
Journal:  Drug Dev Res       Date:  2011-09       Impact factor: 4.360

4.  DNA vaccination with KMP11 and Lutzomyia longipalpis salivary protein protects hamsters against visceral leishmaniasis.

Authors:  Robson A A da Silva; Natália M Tavares; Dirceu Costa; Maiana Pitombo; Larissa Barbosa; Kyioshi Fukutani; Jose C Miranda; Camila I de Oliveira; Jesus G Valenzuela; Aldina Barral; Manuel Soto; Manoel Barral-Netto; Cláudia Brodskyn
Journal:  Acta Trop       Date:  2011-08-22       Impact factor: 3.112

5.  Case Report: Leishmaniasis in a 33-Year-Old Man with Multiple Sclerosis.

Authors:  Alvaro Guerra-Amor; Ane Lopez-Gonzalez; Pau Bosch-Nicolau; Breogan Rodriguez-Acevedo; Ana Zabalza; Elena Sulleiro; Juan Espinosa-Pereiro; Maria Luisa Aznar; Fernando Salvador; Adrián Sánchez-Montalvá; Israel Molina
Journal:  Am J Trop Med Hyg       Date:  2022-07-05       Impact factor: 3.707

6.  Effect of elatol, isolated from red seaweed Laurencia dendroidea, on Leishmania amazonensis.

Authors:  Adriana Oliveira Dos Santos; Phercyles Veiga-Santos; Tânia Ueda-Nakamura; Benedito Prado Dias Filho; Daniela Bueno Sudatti; Everson Miguel Bianco; Renato Crespo Pereira; Celso Vataru Nakamura
Journal:  Mar Drugs       Date:  2010-10-29       Impact factor: 5.118

7.  Is Visceral Leishmaniasis Different in Immunocompromised Patients Without Human Immunodeficiency Virus? A Comparative, Multicenter Retrospective Cohort Analysis.

Authors:  José M Ramos; Rafael León; Esperanza Merino; Marta Montero; Asunción Aljibe; Marino Blanes; Sergio Reus; Vicente Boix; Miguel Salavert; Joaquín Portilla
Journal:  Am J Trop Med Hyg       Date:  2017-10-10       Impact factor: 2.345

Review 8.  Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review.

Authors:  Gláucia F Cota; Marcos R de Sousa; Ana Rabello
Journal:  PLoS Negl Trop Dis       Date:  2011-06-07

9.  Involvement of CD4⁺ Foxp3⁺ regulatory T cells in persistence of Leishmania donovani in the liver of alymphoplastic aly/aly mice.

Authors:  Saruda Tiwananthagorn; Kazuya Iwabuchi; Manabu Ato; Tatsuya Sakurai; Hirotomo Kato; Ken Katakura
Journal:  PLoS Negl Trop Dis       Date:  2012-08-21

10.  Leishmania-HIV co-infection: clinical presentation and outcomes in an urban area in Brazil.

Authors:  Gláucia F Cota; Marcos R de Sousa; Andrea Laender Pessoa de Mendonça; Allan Patrocinio; Luiza Siqueira Assunção; Sidnei Rodrigues de Faria; Ana Rabello
Journal:  PLoS Negl Trop Dis       Date:  2014-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.